2023
Disparities in health condition diagnoses among aging transgender and cisgender medicare beneficiaries, 2008-2017
Hughto J, Varma H, Babbs G, Yee K, Alpert A, Hughes L, Ellison J, Downing J, Shireman T. Disparities in health condition diagnoses among aging transgender and cisgender medicare beneficiaries, 2008-2017. Frontiers In Endocrinology 2023, 14: 1102348. PMID: 36992801, PMCID: PMC10040837, DOI: 10.3389/fendo.2023.1102348.Peer-Reviewed Original ResearchConceptsHealth condition diagnosisCisgender individualsMedicare beneficiariesHealth diagnosisProportion of transgenderMedicare fee-for-service dataGender differencesModifiable risk factorsTrans masculineTransgender individualsTransgender populationCisgender sampleCisgender maleTransgenderMonths of enrollmentCisgenderNon-HispanicCondition diagnosisBetween-group gender differencesDocumented disparitiesNational estimatesHealth conditionsAnalytic sampleEnrollment lengthHighest burden
2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert A, Olszewski A, Kim S, Hess B, Gaballa S, Ayyappan S, Castillo J, Argnani L, Voorhees T, Saba R, Chowdhury S, Vargas F, Reis I, Kwon D, Alexander J, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link B, Logothetis C, Herrera A, Friedberg J, Kahl B, Luminari S, Zinzani P, Lossos I. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances 2022, 6: 2035-2044. PMID: 35196377, PMCID: PMC9006265, DOI: 10.1182/bloodadvances.2021006844.Peer-Reviewed Original ResearchConceptsProgression-free survivalEastern Cooperative Oncology GroupMALT-IPIRituximab maintenanceOverall survivalHerpes zosterAssociated with longer progression-free survivalPerformance status 0 to 1Associated with shorter progression-free survivalHeterogeneous non-Hodgkin lymphomasPresence of B symptomsLonger progression-free survivalShorter progression-free survivalExtranodal marginal zone lymphomaOccurrence of herpes zosterMarginal zone lymphomaInternational Prognosis IndexNon-Hodgkin's lymphomaAdvanced-stage diseaseCooperative Oncology GroupStandard-of-careAdverse prognosis factorsAssociated with occurrenceImpact OSUpfront regimens